Sarepta Therapeutics, Inc.
SRPT
$19.03
-$0.10-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.18B | 2.20B | 2.41B | 2.48B | 2.23B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.18B | 2.20B | 2.41B | 2.48B | 2.23B |
| Cost of Revenue | 1.57B | 1.61B | 1.21B | 1.16B | 1.03B |
| Gross Profit | 614.48M | 592.70M | 1.20B | 1.32B | 1.21B |
| SG&A Expenses | 467.04M | 491.72M | 527.29M | 563.60M | 564.50M |
| Depreciation & Amortization | 2.71M | 2.62M | 2.55M | 2.47M | 2.41M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.18B | 2.86B | 2.50B | 2.48B | 2.35B |
| Operating Income | 1.05M | -657.77M | -86.01M | -932.00K | -117.21M |
| Income Before Tax | 24.47M | -702.23M | -252.19M | -24.13M | -164.19M |
| Income Tax Expenses | -40.59M | 11.19M | 19.33M | 33.83M | 84.20M |
| Earnings from Continuing Operations | 65.06 | -713.41 | -271.51 | -57.96 | -248.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.06M | -713.41M | -271.51M | -57.96M | -248.39M |
| EBIT | 1.05M | -657.77M | -86.01M | -932.00K | -117.21M |
| EBITDA | 46.18M | -613.25M | -36.28M | 40.15M | -78.25M |
| EPS Basic | 0.67 | -7.08 | -2.73 | -0.58 | -2.52 |
| Normalized Basic EPS | -0.14 | -4.08 | -0.49 | 0.07 | -0.64 |
| EPS Diluted | 0.26 | -7.21 | -2.89 | -0.76 | -2.57 |
| Normalized Diluted EPS | -0.48 | -4.14 | -0.67 | -0.11 | -0.77 |
| Average Basic Shares Outstanding | 408.02M | 400.40M | 391.89M | 387.04M | 383.65M |
| Average Diluted Shares Outstanding | 433.57M | 409.02M | 412.70M | 412.91M | 405.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |